SEC Company Response from IGC Pharma, Inc. (IGC) (CIK 0001326205) (IGC) — Apr 15, 2014
IGC Pharma, Inc. (IGC) (CIK 0001326205)
Date: April 15, 2014 · CIK: 0001326205 · Accession: 0001185185-14-001002
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-32830
Letter
VIA EDGAR Securities and Exchange Commission Office of Beverages, Apparel and Mining Form 8-K Filed January 31, 2014 Form 8-K Filed February 6, 2014 Response Dated March 10, 2014 File No. 001-32830
Dear Ms. Jenkins:
On Tuesday April 15, 2014 we spoke with Assistant Chief Accountant Ms. Nasreen Mohammed, and we were granted an extension of ten more business days for the filing of our response to the referenced comments.
We are very grateful for the Staff’s guidance, discussions over the phone, and understanding of our situation. We will file our response by April 29, 2014.
Sincerely,
ss:
Show Raw Text
CORRESP
1
filename1.htm
indiaglobal-corresp041514.htm
India Globalization Capital, Inc.
4336 Montgomery Avenue
Bethesda, Maryland 20814
Phone: 301-983-0998
Fax: 240-465-0273
April 15, 2014
VIA EDGAR
Securities and Exchange Commission
100 F. Street, N.E.
Washington, D.C. 20549
Attn: Ms. Tia Jenkins
Senior Assistant Chief Accountant
Office of Beverages, Apparel and Mining
Re:
India Globalization Capital, Inc.
Form 10-K for the Fiscal Year Ended March 31, 2013
Filed July 16, 2013
Form 8-K Filed January 31, 2014
Form 8-K Filed February 6, 2014
Response Dated March 10, 2014
File No. 001-32830
Dear Ms. Jenkins:
On Tuesday April 15, 2014 we spoke with Assistant Chief Accountant Ms. Nasreen Mohammed, and we were granted an extension of ten more business days for the filing of our response to the referenced comments.
We are very grateful for the Staff’s guidance, discussions over the phone, and understanding of our situation. We will file our response by April 29, 2014.
Sincerely,
ss:
India Globalization Capital, Inc.
Ram Mukunda,
Chief Executive Office